問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳威志
下載
2025-11-01 - 2030-12-31
Condition/Disease
The efficacy of lunsekimig was assessed by measuring the annualized incidence of moderate to severe COPD exacerbations.
Test Drug
Lunsekimig/ SAR443765
Participate Sites8Sites
Not yet recruiting1Sites
Recruiting7Sites
2023-12-08 - 2024-09-30
Participate Sites7Sites
2023-07-03 - 2026-12-31
Participate Sites4Sites
Recruiting4Sites
2023-10-01 - 2026-12-31
Participate Sites10Sites
Recruiting10Sites
2022-01-31 - 2024-12-10
2020-11-02 - 2024-04-30
2022-09-01 - 2025-02-14
2024-06-20 - 2027-09-01
Participate Sites6Sites
Recruiting6Sites
2023-06-01 - 2025-12-31
Participate Sites5Sites
Recruiting5Sites
2025-10-01 - 2027-10-01
全部
